[go: up one dir, main page]

WO2015053589A1 - Composition de prévention ou de traitement d'une maladie auto-immune, utilisant un complexe de metformine et de statine - Google Patents

Composition de prévention ou de traitement d'une maladie auto-immune, utilisant un complexe de metformine et de statine Download PDF

Info

Publication number
WO2015053589A1
WO2015053589A1 PCT/KR2014/009538 KR2014009538W WO2015053589A1 WO 2015053589 A1 WO2015053589 A1 WO 2015053589A1 KR 2014009538 W KR2014009538 W KR 2014009538W WO 2015053589 A1 WO2015053589 A1 WO 2015053589A1
Authority
WO
WIPO (PCT)
Prior art keywords
metformin
disease
coenzyme
statins
diseases
Prior art date
Application number
PCT/KR2014/009538
Other languages
English (en)
Korean (ko)
Inventor
조미라
박성환
박민정
전주연
이성희
변재경
정정희
이정아
곽승기
이주하
주지현
양철우
나현식
이은정
이선영
양은지
손혜진
Original Assignee
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020140134451A external-priority patent/KR101627045B1/ko
Priority claimed from KR1020140134452A external-priority patent/KR101627046B1/ko
Application filed by 가톨릭대학교 산학협력단 filed Critical 가톨릭대학교 산학협력단
Publication of WO2015053589A1 publication Critical patent/WO2015053589A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • composition for preventing or treating autoimmune diseases may include a pharmaceutically effective amount of metformin and statin compounds or salts thereof alone or may include one or more pharmaceutically acceptable carriers, excipients or diluents.
  • the pharmaceutically effective amount herein refers to an amount sufficient to prevent, ameliorate and treat the symptoms of autoimmune diseases.
  • 1A and 1B show the results of FACS analysis of the production of IL-17 and IFN- ⁇ in cells after treatment with metformin and roschvastatin alone and in combination under Th17 cell differentiation conditions.
  • biotinylated anti-TNF- ⁇ or anti-IL-6 was reacted for 2 hours at room temperature, followed by 4 washes, and the ExtraAvidin-Alkaline Phosphatase conjugate was diluted and added for 2 hours at room temperature, followed by PNPP / DEA. The solution was added and developed, and the absorbance was measured at 405 nm.
  • One group and inflammatory bowel disease-inducing animals were divided into four groups, which were administered the combination formulations of the metformin 50 mg / kg, coenzyme Q10 5 mg / kg and rosuvastatin 10 mg / kg of the present invention, metformin, coenzyme Q10 and Rosuvastatin co-administered group and sulfasalazine (sulfasalazine) group were administered orally at the concentration of 5 mg each drug 3 days after disease induction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition destinée à la prévention ou au traitement de maladies auto-immunes, utilisant un complexe contenant de la metformine, une statine et, facultativement, la coenzyme Q10. Selon la présente invention, une composition pharmaceutique de prévention ou de traitement de maladies auto-immunes, qui est un complexe contenant de la metformine, une statine et, facultativement, la coenzyme Q10, en tant qu'ingrédients actifs, peut efficacement inhiber la génération de cytokines inflammatoires, peut inhiber la génération de lymphocytes B produisant des anticorps ou réduire leur activité, a des effets d'inhibition de la différenciation des ostéoclastes et d'inhibition de la destruction des articulations, et présente un effet remarquable d'inhibition de la génération de cellules spumeuses, qui génèrent les cellules progénitrices de plaques athérosclérotiques, et peut ainsi être utile en tant qu'agent de traitement de maladies immunologiques comprenant des maladies auto-immunes.
PCT/KR2014/009538 2013-10-11 2014-10-10 Composition de prévention ou de traitement d'une maladie auto-immune, utilisant un complexe de metformine et de statine WO2015053589A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR20130121108 2013-10-11
KR10-2013-0121108 2013-10-11
KR20140030896 2014-03-17
KR10-2014-0030896 2014-03-17
KR1020140134451A KR101627045B1 (ko) 2013-10-11 2014-10-06 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR10-2014-0134452 2014-10-06
KR10-2014-0134451 2014-10-06
KR1020140134452A KR101627046B1 (ko) 2014-03-17 2014-10-06 메트포민, 코엔자임 q10 및 스타틴을 유효성분으로 포함하는 복합제제 및 이의 면역질환 치료를 위한 용도

Publications (1)

Publication Number Publication Date
WO2015053589A1 true WO2015053589A1 (fr) 2015-04-16

Family

ID=52813350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/009538 WO2015053589A1 (fr) 2013-10-11 2014-10-10 Composition de prévention ou de traitement d'une maladie auto-immune, utilisant un complexe de metformine et de statine

Country Status (1)

Country Link
WO (1) WO2015053589A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119405639A (zh) * 2025-01-07 2025-02-11 山东大学 盐酸二甲双胍在制备抗白斑综合征药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209128A1 (en) * 1999-02-06 2005-09-22 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US20130035316A1 (en) * 2009-12-30 2013-02-07 Bcworld Pharm. Co., Ltd. Pharmaceutical composition comprising metformin and rosuvastatin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209128A1 (en) * 1999-02-06 2005-09-22 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US20130035316A1 (en) * 2009-12-30 2013-02-07 Bcworld Pharm. Co., Ltd. Pharmaceutical composition comprising metformin and rosuvastatin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BESSLER, HANNA ET AL., ''COENZYME Q10 DECREASES TNF- A AND IL -2 SECRETION BY HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS ET AL., JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, vol. 56, 2010, pages 77 - 81 *
KRYSIAK, ROBERT ET AL.: "Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose", ATHEROSCLEROSIS, vol. 225, 2012, pages 403 - 407 *
PAINTLIA, AJAIB S. ET AL.: "Combinatorial effect of metformin and lovastatin impedes T- cell autoimmunity and neurodegeneration in experimental autoimmune encephalomyelitis", JOURNAL OF CLINICAL & CELLULAR IMMUNOLOGY, vol. 4, no. 3, 30 June 2013 (2013-06-30) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119405639A (zh) * 2025-01-07 2025-02-11 山东大学 盐酸二甲双胍在制备抗白斑综合征药物中的应用
CN119405639B (zh) * 2025-01-07 2025-03-14 山东大学 盐酸二甲双胍在制备抗白斑综合征药物中的应用

Similar Documents

Publication Publication Date Title
WO2017022962A1 (fr) Composition pour la prévention ou le traitement d'une maladie immunitaire, comprenant un inhibiteur de la rip kinase en tant que principe actif
WO2016093599A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie métabolique, comprenant des bactéries bacteroides acidifaciens utilisées comme principe actif efficace
WO2011142514A1 (fr) Composition contenant du pias3 comme ingrédient actif pour la prévention ou le traitement d'un cancer ou d'une maladie immune
WO2011159124A2 (fr) Nouveau dérivé de benzoxazole présentant une activité inhibitrice contre l'interleukine 6, procédé pour le préparer, et composition pharmaceutique le contenant
WO2011159137A2 (fr) Nouvelle thio-urée ou nouveau dérivé d'urée, procédé permettant leur préparation, et composition pharmaceutique destinée à prévenir ou à traiter le sida, les contenant en tant que principe actif
WO2015026215A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies immunitaires ou des maladies inflammatoires, contenant un composé de dérivé de biguanide comme principe actif
WO2011115456A2 (fr) Antagoniste double tnf-α et tweak pour la prophylaxie et le traitement des maladies autoimmunes
WO2015167243A1 (fr) Nouveau composé ayant un effet thérapeutique sur les maladies immunitaires et utilisation de ce composé
WO2011115458A2 (fr) Antagoniste double pour le tnf-α et l'il-21 dans la prévention et le traitement de maladies auto-immunes
WO2019216623A1 (fr) Vaccin cellulaire possédant une tolérance immunitaire pour le traitement du diabète et de l'obésité et procédé de production de cellules sécrétrices d'insuline
WO2015053589A1 (fr) Composition de prévention ou de traitement d'une maladie auto-immune, utilisant un complexe de metformine et de statine
WO2015076430A1 (fr) Composition pour la prévention ou le traitement de maladies immunes, contenant de la metformine en tant que principe actif
WO2016111523A2 (fr) Antagoniste de hnf4-a et utilisation associée
WO2021149971A1 (fr) Nouveau composé et son utilisation
WO2023249228A1 (fr) Nouveau composé et son utilisation pour traiter des maladies auto-immunes
WO2022164122A1 (fr) Composition pharmaceutique immunosuppressive comprenant un dérivé de benzène comme immunosuppresseur
WO2023277584A1 (fr) Composition pour éliminer les cellules sénescentes comprenant un composé sélénié en tant que principe actif
WO2022260434A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie auto-immune
WO2020209476A1 (fr) Composition comprenant un complexe minéral argileux pour la prévention, le soulagement et le traitement d'une maladie intestinale inflammatoire, procédé de préparation pour composition, et procédé pour soulager et traiter une maladie intestinale inflammatoire
EP4117699A1 (fr) Composition topique comprenant un extrait d'herbes combinées comprenant longanae arillus pour le traitement ou le soulagement de l'ulcère cutané et son utilisation
WO2014021637A1 (fr) Composition comprenant du rébamipide comme ingrédient actif pour prévenir ou traiter l'hyperlipidémie et des maladies lui sont associées
WO2015111971A1 (fr) Composition pharmaceutique contenant un ligand gpr119 comme principe actif pour prévenir ou traiter une stéatose hépatique non alcoolique
WO2011074881A2 (fr) Substances destinées à inhiber l'expression de gènes pour la sensibilité à des troubles allergiques
WO2024128335A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies osseuses
WO2020080653A1 (fr) Caractéristiques structurales et fonctionnelles d'une cellule treg induisant un polysaccharide dérivé de levure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14852072

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14852072

Country of ref document: EP

Kind code of ref document: A1